Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.
This study has been completed.
Study NCT00249782   Information provided by Allergan
First Received: November 3, 2005   Last Updated: September 8, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Rosacea
More general conditions related to this trial
Skin Diseases
Interventions listed in this trial
Vehicle control, 2x/day
ACZONE (dapsone) Gel, 5%, 2x/day
ACZONE (dapsone) Gel, 5%, 1x/day
Additional drug interventions recognized in this trial
Dapsone
Metronidazole
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antimalarials
Antiparasitic Agents
Antiprotozoal Agents
Enzyme Inhibitors
Folic Acid Antagonists
Leprostatic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Allergan


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services